Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-Reductase Type II) Genes in Prostate Cancer

Simard J, Dumont M, Labuda, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer. 2003; 10(2): 225-259.10.1677/erc.0.0100225Search in Google Scholar

Takaku H, Minagawa W, Takagi M, Nashimot M. The N-terminal half-domain of the long form of tRNase Z is required for the Rnase 65 activity. Nucleic Acids Res. 2004; 32(15): 4429-4438.10.1093/nar/gkh774Search in Google Scholar

Kover W, Guevara C, Chen, Y. Neuteboom S, Bookstein R, Tavtigian S, Lees E. The product of candidate prostate cancer susceptibility gene ELAC2 interacts with the γ-tubulin complex. Int. J Cancer. 2003; 104(3): 283-288.Search in Google Scholar

Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin A, Nathanson KL, Wein AJ, Malkowicz B. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 2000; 67(4): 1010-1019.10.1086/303096Search in Google Scholar

Thigpen AE, Cala KM, Russell DW. Characterization of Chinese hamster ovary cell lines expressing human steroid 5α-reductase isozymes. J Biol Chem. 1993; 268 (23): 17404-17412.10.1016/S0021-9258(19)85349-8Search in Google Scholar

Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995; 55(18): 3973-3975.Search in Google Scholar

Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JKV. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 1997; 57(6): 1020-1022.Search in Google Scholar

Labrie F, Sagimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N. Structure of human type II 5α-reductase gene. Endocrinology. 1992; 131(3): 1571-1573.10.1210/endo.131.3.15054841505484Search in Google Scholar

Jaffe JM, Malkowicz B, Walker AH, MacBride S, Peschel R, Tomaszewski J, Arsdalen KV, Wein AJ, Rebbeck TR. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 2000; 60(6): 1626-1630.Search in Google Scholar

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215.10.1093/nar/16.3.12153347653344216Search in Google Scholar

Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate. 2004; 59(1): 69-76.10.1002/pros.1035814991867Search in Google Scholar

Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu J, Feng Z, Ostrander EA. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study. Cancer Epidemiol Biomarkers Prev. 2003; 12(9): 876-881.Search in Google Scholar

Camp NJ, Swensen J, Horne BD, Farnham JM, Thomas A, Cannon-Albright LA, Tavtigian SV. Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and famlial early-onset prostate cancer. Genet Epidemiol. 2005; 28(3): 232-243.10.1002/gepi.2005415593091Search in Google Scholar

Meitz JC, Edwards SM, Easton DF, Murkin A, Ardern-Jones A, Jackson RA, Williams S, Dearnaley DP, Stratton MR, Houlston RS. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis age of onset of disease. Br J Cancer. 2002; 87(8): 905-908.10.1038/sj.bjc.6600564237617912373607Search in Google Scholar

Adler D, Kanji N, Trpkoy K, Fick G, Hughes RM. HPC2/ELAC2 gene variants associated with incident prostate cancer. J Hum Genet. 2003; 48(12): 634-638.10.1007/s10038-003-0091-614625808Search in Google Scholar

Rökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TLJ, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res. 2001; 61(16): 6038-6041.Search in Google Scholar

Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schald DJ, Thibodeau SN. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 2001; 61(17): 6494-6499.Search in Google Scholar

Vesprini D, Nam RK, Trachtenberg J, Jewett MAS, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet. 2001; 68(4): 912-917.10.1086/319502Search in Google Scholar

Yokomizo A, Koga H, Kinukawa N, Tsukamoto T, Hirao Y, Akaza H, Mori M, Naito S. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate. 2004; 61(3): 248-252.10.1002/pros.20107Search in Google Scholar

Makridakis NM, Reichardt JK. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev. 2001; 23(1): 24-29.10.1093/oxfordjournals.epirev.a000791Search in Google Scholar

Latil AG, Azzouzi R, Cancel GS, Gulllaume EC, Cochan-Priollet C, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 2001; 92(5): 1130-1137.10.1002/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-BSearch in Google Scholar

Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JKV. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2001; 10(10): 1077-1082.Search in Google Scholar

Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H. The association of 5α-reductase type II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 2007; 26(2): 100-107.10.1089/dna.2006.0534Search in Google Scholar

Nam RK, Toi A, Vesprini D, Ho M, Sweet J, Trachtenberg J, Jewett MAS, Narod SA. V89L polymorphism of type-2, 5α-reductase enzyme gene predicts prostate cancer presence and progression. Urology. 2001; 57 (1): 199-204.10.1016/S0090-4295(00)00928-6Search in Google Scholar

Neslund-Dudas C, Bock CH, Monaghan K, Nock NL, Yang JJ, Rundle A, Tang D, Rybicki BA. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate. 2007; 67(15): 1654-1663.10.1002/pros.20625Search in Google Scholar

Li Z, Habuchi T, Mitsumori K, Kamoto T, Kinoshitu H, Segawa T, Ogava O, Kato T. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol. 2003; 169(6): 2378-2381.10.1097/01.ju.0000056152.57018.31Search in Google Scholar

Rajender S, Vuayalakshmi K, Pooja S, Madhavi S, Paul SFD, Vettriselvi V, Shroff S, Singh L, Thangaraj K. Longer (TA)_n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl. 2009; 30(6): 703-710.10.2164/jandrol.108.007377Search in Google Scholar

Soderstrom TG, Bjelfman C, Brekkan E, Ask B, Egevad L, Norlen BJ, Rane A. Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab. 2001; 86(2): 855-858.Search in Google Scholar